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In general, ulcerative colitis (UC) is defined as idiopathic inflammation limited to 
colorectum except backwash ileititis and postcolectomy pouchitis. However, UC is also 
considered to be a systemic disease because of not only colonic inflammation but also 
joint, skin, and acute hepatic involvement. Recently, there are several reports UC 
patients with gastroduodenitis or enteritis [1-4].
  
Cases of gastroduodenitis or enteritis 
associated with UC are clinically rare but important issue for gastroenterologists in the 
point of no optimal treatment established. Here, we report a case of the postoperative 












A 19-year old female was referred to our hospital in January 2007 because of severe 
abdominal pain and hematochezia. Four years before admission, she had been 
diagnosed with ulcerative colitis (pancolitis type) both endoscopically and histologically. 
She was treated with oral salazosulfapyridine and corticosteroids. However, she 
required a dose-up of corticosteroids, mesalamine and granulocytapheresis because she 
did not achieve remission. But in January 2007, the patient was readmitted to our 
hospital because of exacerbation of her UC. After the additional treatment with 
tacrolimus and azathioprine (AZA), her symptom was improved and corticosteroids was 
gradually tapered off and completely stopped after 5 months. But, the patient was 
readmitted because of relapse of her UC in September 2007. On admission, the body 
temperature was 37.3 C º and laboratory data showed slight anemia and mild elevation 






, Hb 11.8 g/dl, Ht 
36.2 %, CRP 0.4 mg/dl). Colonoscopy disclosed diffuse edema, loss of vascular pattern 
and easy-bleeding from the rectum up to cecum. The serology test, 
immunohistochemistry and mucosal PCR were negative for cytomegalovirus. Both 
esophago-gastro-duodenoscopy (EGD) and radiographic visualization of small intestine 
revealed normal findings. Histological examination showed no infiltration of 
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inflammatory cells in gastroduodenal mucosa. Since she repeated flare-up of her UC 
despite the use of immunomodulators, proctocolectomy with IPAA (ileal-pouch-anal 
anastomosis) and a temporary diverting ileostomy was performed in the end of 
September. Histological diagnosis of the colectomy specimen was compatible with 
pancolitis UC, and no inflammation and granuloma was not detected in the terminal 
ileum. The postoperative course was uneventful and her condition was stable without 
any medication.  
In February 2008, however, she was admitted again because of frequent vomiting and 
severe epigastralgia at 65 days after colectomy. EGD revealed edema, granularity in the 
duodenal bulb and the second portion of duodenum (Figure 1). Histological 
examination taken from the duodenum showed neutrophil infiltration in the submucosa 
and cryptisis with no findings of non-caseous granuloma (Figure 2). Also, neither 
villous atrophy nor crypt hypertrophy was observed in the biopsy specimen, which 
suggested no possibility of celiac disease or autoimmune enteropathy of her disease. 
Immunohistochemistry and serological test was negative for H.pylori. Stool culture was 
also negative for Clostridium difficile. Taken together, we diagnosed her having 
duodenitis associated with UC. Her abdominal pain deteriorated despite the prompt 
treatment with mesalamine. An abdominal CT revealed the marked distention and wall 
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thickening and edema of small intestine (Figure 3), which was suggestive of the 
occurrence of small-intestinal inflammation associated with UC. Additionally, pouch 
endoscopic findings revealed diffuse edema, loss of vascular pattern, and small erosions 
with pus in the pouch. Histological findings of biopsy specimen were compatible with 
pouchitis. Infliximab (IFX) (5mg/kg) was promptly initiated. She rapidly responded to 
this treatment, and EGD at 109 days after administration of IFX revealed significant 
improvement of duodenitis when seen in June 2008 (Figure 4). Pouch endoscopy also 
revealed improvement of her pouchitis. We performed intracellular cytokine assay with 
peripheral CD4 T cells before and after IFX therapy. The ratio of T-helper (Th) 1 
(IFN-γ) /Th2 (interleukin (IL)-4) was increased (31.7) at two weeks after IFX therapy 
compared to that before (14.5). She was in clinical remission with maintenance therapy 




Gut inflammation in UC has been considered to limited to the large bowel. Several 
cases of UC with gastrointestinal involvement have been reported [5-7]. Rubstein et al. 
reported 5 UC cases with duodenal and jejunal involvements [7]. Hori et al reported the 
prevalence (19/250: 7.6%) and significant risk factors (pancolitis and a lower dose of 
predonisolone) of gastroduodenitis associated UC by performing prospective 
esophagogastroduodenoscopy for 250 Japanese patients with UC [8]. Since the 
endoscopic features mimicking those of colon are sometimes helpful for making 
diagnosis of gastroduodenitis related to UC, EGD is available for examining whether 
gastroduodenitis would occur in patients with UC after colectomy [9, 16]. It was 
reported that duodenitis associated with UC occurred after colectomy tends to be 
accompanied by pouchitis as in our present case [9]. These reports suggested that both 
EGD and pouch endoscopy should be performed when patients with UC taking 
colectomy complain of abdominal symptoms. 
Thus, much attention is focused on UC patients with gastroduodenitis or enteritis, 
although the etiology is still unknown. Recently, Gooding et al. reported 8 cases of 
idiopathic small-intestinal inflammation after colectomy for UC including their own 
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case [9]. In seven out of eight cases, immunosuppressive therapies such as 
corticosteroids or azathioprine were effective. Finally, they concluded that patients with 
idiopathic small intestinal inflammation should be treated by immunosuppressants 
promptly after the diagnosis was made because these patients responded well to 
immunosuppressive therapies. 
However, no standard therapy on patients with small intestinal inflammation associated 
with UC has been established yet. In present case, our patient was promptly treated with 
the combination of IFX and three days methylprednisolone at diagnosis of panenteritis 
after colectomy. The reason why we administered IFX alternative to immunomodulators 
is due to that she had experienced flares up of her UC several times before colectomy 
irrespective of using immunomodulators such as AZA and tacrolimus. At present, she 
kept clinical remission with maintenance therapy of IFX after completely tapering off 
corticosteroid. 
It is well known that IFX, a chimeric monoclonal antibody directed against tumor 
necrosis factor-α, is effective for patients with Crohn’s disease and UC [10-12]. 
However, whether IFX can be effective for UC patients with small intestinal 
inflammation after colectomy remains unclear. In present case, interestingly, her 
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abdominal symptoms subsided with the increase of the Th1/Th2 ratio of peripheral CD4 
T cells after administration of IFX. This intracellular cytokine data suggested that the 
pathophysiology of small intestinal inflammation occurred after colectomy in patients 
with UC might be associated with a Th2 cytokine phenotype. Our several reports 
showed that skewing toward Th1 cytokine profile could lead to reduction of disease 
activity of UC [13-15]. Therefore, we expect IFX to be a promising therapy for small 
intestinal inflammation associated with UC by its immunomodulative effect, but it 
should be necessary to perform clinical trial with IFX for a larger number of patients 
with small-intestinal inflammation associated with UC. 
In conclusion, this is the first case of a patient with postoperative occurrence of small 
intestinal inflammation associated with UC successfully treated with IFX. Most 
importantly, if we encounter patients with UC who complained of unexplained 
abdominal pain and diarrhea after undertaking colectomy, we should consider the 
occurrence of small intestinal inflammation as a differential diagnosis because prompt 
diagnosis results in excellent outcome.  
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Figure 1: Esophago-gastro-duodenoscopy disclosed edema, granularity in the duodenal 
bulb (A, B) and the second portion of duodenum (C).  
 
Figure 2: Histological examination taken from the duodenum showed neutrophil 
infiltration in the submucosa and cryptisis with no findings of non-caseous granuloma. 
 
Figure 3: Abdominal CT revealed the marked distention and wall thickening and edema 
of whole small intestine 
 
Figure 4: Esophago-gastro-duodenoscopy performed at 109 days after infliximab 
treatment revealed significant improvement of duodenitis both in the duodenal bulb (A) 
and the second portion of duodenum (B).  
 
 
 
